Thalidomide causes birth defects by hijacking a protein in the body’s cellular cleanup system, turning it against proteins essential for fetal development. The drug was marketed as a safe sedative in the late 1950s and early 1960s, and it is estimated that as many as 100,000 babies were affected before it was pulled from most markets. Scientists didn’t fully understand the molecular mechanism until decades later, but the picture is now remarkably clear.
The Protein Thalidomide Targets
Inside your cells, a protein called cereblon acts as a quality-control worker. It’s part of a larger molecular machine (an E3 ubiquitin ligase) whose job is to tag damaged or unwanted proteins for destruction. Under normal conditions, cereblon recognizes specific proteins, attaches a small chemical label to them, and sends them to the cell’s recycling center, the proteasome, where they’re broken apart.
Thalidomide physically binds to cereblon and changes its targeting behavior. The drug acts like a piece of molecular glue: it latches onto cereblon on one side and grabs proteins that cereblon would normally ignore on the other, locking them together. Once stuck to cereblon, these proteins get tagged for destruction and are degraded. Scientists call these unintended targets “neosubstrates” because they are new, abnormal targets that cereblon would never touch on its own.
How It Destroys Proteins Needed for Limb Growth
In 2018, two independent research groups identified the key neosubstrate behind thalidomide’s birth defects: a transcription factor called SALL4. Transcription factors are proteins that switch genes on and off during development. SALL4 is critical for directing limb formation, ear development, and the growth of several internal organs in the embryo.
When thalidomide glues SALL4 to cereblon, the cell destroys SALL4 as if it were waste. Without enough SALL4, the genetic instructions for building arms, legs, and other structures can’t be read properly. The result is that limbs either fail to form or develop severely shortened, a condition called phocomelia, where hands or feet may attach almost directly to the torso. The connection between SALL4 and thalidomide’s effects is strengthened by the fact that children born with inherited SALL4 gene mutations develop strikingly similar limb and organ abnormalities, even without any drug exposure.
SALL4 shares a structural feature with other thalidomide targets: a small loop containing a specific amino acid (glycine) that fits neatly into the binding pocket created when thalidomide sits inside cereblon. This structural match is what makes SALL4 vulnerable to drug-induced destruction.
Why Separating the “Safe” Form Didn’t Work
Thalidomide exists as two mirror-image versions of the same molecule, like a left and right hand. These are called the R and S enantiomers. Early research suggested that the S form was primarily responsible for birth defects, while the R form provided the sedative effect. This led to the idea that selling only the “safe” R version could have prevented the tragedy.
That idea doesn’t hold up. In the human body, the two forms convert back and forth into each other spontaneously. The interconversion half-life in human blood is roughly 2 to 6 hours, meaning that even if you swallowed a pure dose of the R form, a significant portion would become the dangerous S form before your body could eliminate it. The elimination half-life is 3 to 8 hours, so the drug converts faster than it’s cleared. There is no practical way to keep only the “safe” version in the bloodstream.
The Critical Window of Vulnerability
The damage occurs during a narrow period: roughly days 20 through 36 after fertilization. This is when the embryo’s limbs, ears, eyes, and major organs are first forming. The specific defect depends on exactly when exposure happens during that window. A dose on day 21 might affect the ears, while exposure around day 24 to 28 might cause arm malformations, and later exposure could affect the legs.
Taking the drug before day 20 or after day 36 generally did not cause major structural defects. This is why some women who took thalidomide during pregnancy had unaffected babies: they happened to take it outside this critical window. But the window overlaps with a period when many women did not yet know they were pregnant, which is part of why the disaster was so widespread.
The Range of Birth Defects
Limb malformations are the most recognized feature of thalidomide embryopathy, but the drug caused a much broader spectrum of harm. Affected children could be born with complete absence of one or more limbs, shortened limbs missing the upper bones, or thumb abnormalities. Beyond the limbs, thalidomide caused damage to the ears (ranging from small, malformed ears to complete absence of external ears), eyes (abnormally small eyes, missing eyes, or misaligned eyes), and internal organs including the heart, kidneys, and gastrointestinal tract. Facial birthmarks from abnormal blood vessel growth were also common.
Of the estimated 10,000 or more babies born alive with thalidomide-related defects worldwide, fewer than 3,000 survive today. Many affected infants did not survive their first year due to severe internal organ malformations.
How the Tragedy Changed Drug Regulation
Before thalidomide, drug companies in the United States only needed to show a drug was safe before selling it. They did not need to prove it actually worked. In October 1962, Congress passed the Kefauver-Harris Drug Amendments, which fundamentally reshaped how drugs reach the market. Companies now had to provide substantial evidence of effectiveness through adequate and well-controlled studies. The FDA also gained the power to approve or reject a drug before it could be sold, rather than simply receiving a notification from the manufacturer.
The amendments also required informed consent from participants in clinical trials, formalized manufacturing quality standards, mandated reporting of adverse events, and transferred oversight of prescription drug advertising to the FDA. These requirements became the foundation for modern drug regulation globally.
Thalidomide Is Still Used Today
Despite its history, thalidomide is now an FDA-approved treatment for multiple myeloma (a blood cancer) and a painful skin complication of leprosy. The same mechanism that makes it dangerous to embryos, its ability to redirect cereblon toward destroying specific proteins, turns out to be useful against cancer cells. It also suppresses parts of the immune system that drive inflammation.
To prevent any repeat of the original disaster, thalidomide is only available in the U.S. through a tightly restricted program called THALOMID REMS. Only certified prescribers can write prescriptions and only certified pharmacies can fill them. Women who can become pregnant must use two forms of birth control simultaneously, undergo pregnancy testing before starting treatment, then weekly for the first month and at least monthly after that. Men taking the drug must use condoms during treatment and for four weeks afterward, and cannot donate sperm. All patients must complete a mandatory monthly survey to continue receiving the medication.